Halma ensures its strong market share in mostly concentrated sectors is protected and that it can continue to yield pricing power through differentiation by allocating approximately 5% of sales to R&D ...

Halma continues to maintain its health growth trajectory, comprised of a broadly equal contribution from M&A and organic growth. The company is a leader in a number of segments within its industry, ...

Halma has a strong track record of dividend growth and operates in a defensive business area. The company expects good organic revenue growth despite negative market conditions in Asia Pacific.

Halma funds acquisitions through organic growth, which we believe is more maintainable than issuing shares or taking on debt. Halma’s decentralized strategy regularly offers business owners a more ...

June 12 (Reuters) - British health and safety device maker Halma (HLMA.L), opens new tab on Thursday forecast higher revenue growth for fiscal year 2026 and beat annual profit expectations, sending ...